plasma levels  (Novus Biologicals)

Journal: The Journal of Prevention of Alzheimer's Disease

Article Title: Evaluation of plasma p-tau217 biomarkers in detecting amyloid pathology and predicting cognitive outcomes: Observations from Japanese Alzheimer’s disease neuroimaging initiative cohort

doi: 10.1016/j.tjpad.2026.100502

Figure Lengend Snippet: Diagnostic performance and cutoff points of plasma p-tau217 biomarkers for detecting amyloid pathology ( A ) ROC curves showing the AUCs of each plasma biomarker in discriminating amyloid pathology, as defined by the CSF Aβ42/Aβ40 ratio. ( B ) Simoa p-tau217, ( C ) Lumipulse p-tau217, and ( D ) Lumipulse p-tau217/Aβ42 × 10³ plots are shown. The red solid lines indicate the single-point cutoffs determined by the maximum Youden index. The red dashed lines represent the two-point cutoffs achieving >95% sensitivity and >95% specificity, with the intermediate zones shaded in red. For Lumipulse p-tau217, only one cutoff is shown as it meets both criteria using a single threshold. For Lumipulse p-tau217/Aβ42, the single-point and two-point cutoffs were identical, and thus only the red solid line is displayed. FDA-approved two-point cutoffs are indicated by blue dashed lines, with the intermediate zones shaded in blue.

Article Snippet: Plasma p-tau217 levels measured using Lumipulse and Simoa assays were highly correlated (p < 0.001).

Techniques: Diagnostic Assay, Clinical Proteomics, Biomarker Discovery

Journal: The Journal of Prevention of Alzheimer's Disease

Article Title: Evaluation of plasma p-tau217 biomarkers in detecting amyloid pathology and predicting cognitive outcomes: Observations from Japanese Alzheimer’s disease neuroimaging initiative cohort

doi: 10.1016/j.tjpad.2026.100502

Figure Lengend Snippet: Kaplan–Meier curves showing risk of conversion to AD dementia based on plasma p-tau217 biomarkers Participants were stratified into high (above cutoff) and low (below cutoff) groups using cutoff values determined by the maximum Youden index. ( A ) Simoa p-tau217, ( B ) Lumipulse p-tau217, and ( C ) Lumipulse p-tau217/Aβ42 ratio. Participants in the high-biomarker group exhibited significantly higher rates of conversion to AD dementia during follow-up. Log-rank test p-values were as follows: Simoa p-tau217 (p = 0.002), Lumipulse p-tau217 (p < 0.001), and Lumipulse p-tau217/Aβ42 (p < 0.001). Numbers at risk are shown in the bottom.

Article Snippet: Plasma p-tau217 levels measured using Lumipulse and Simoa assays were highly correlated (p < 0.001).

Techniques: Clinical Proteomics, Biomarker Discovery

Journal: Alzheimer's Research & Therapy

Article Title: Diagnostic performance of plasma GFAP in preclinical stages of Alzheimer’s disease using the Lumipulse platform

doi: 10.1186/s13195-026-02012-9

Figure Lengend Snippet: Correlation between plasma GFAP an CSF biomarkers. Non-adjusted correlation between plasma GFAP and CSF biomarkers. Y axis corresponds to plasma GFAP values in all plots. X axis refers to CSF biomarker levels. The dots represent a pair of values of both variables for each observation. The green ones are those corresponding to amyloid-negative subjects (according to CSF Aβ42/Aβ40), and the blue ones represent the amyloid-positive subjects. The red line is the regression line, and the shaded area represents the 95% confidence interval. Abbreviations: GFAP, glial fibrillary acidic protein. CSF, cerebrospinal fluid. Aβ, beta-amyloid. p-tau, phosphorylated tau. t-tau, total tau

Article Snippet: Correlation plot of plasma GFAP levels measured with both Lumipulse and SIMOA techniques.

Techniques: Clinical Proteomics, Biomarker Discovery

Journal: Alzheimer's Research & Therapy

Article Title: Diagnostic performance of plasma GFAP in preclinical stages of Alzheimer’s disease using the Lumipulse platform

doi: 10.1186/s13195-026-02012-9

Figure Lengend Snippet: Differences in plasma GFAP according to AT group. Differences in plasma GFAP according to AT group. The figure shows a box and whiskers plot of plasma GFAP by AT groups. The X axis represents the different groups according to the CSF profile. Y axis corresponds to plasma GFAP concentrations expressed in pg/ml. The boxes show the interquartile range (being the upper boundary Q3, and the lower boundary, Q1). The line inside the box corresponds to the median of the sample, and the whiskers represent the maximum (upper) and minimum (lower) values. Dots indicate individual values. Significant differences are indicated with a horizontal line and three asterisks between the boxes. Abbreviations: GFAP, glial fibrillary acidic protein. A, amyloid. T, tau

Article Snippet: Correlation plot of plasma GFAP levels measured with both Lumipulse and SIMOA techniques.

Techniques: Clinical Proteomics

Journal: Alzheimer's Research & Therapy

Article Title: Diagnostic performance of plasma GFAP in preclinical stages of Alzheimer’s disease using the Lumipulse platform

doi: 10.1186/s13195-026-02012-9

Figure Lengend Snippet: Ability of plasma GFAP to discriminate between A-/A+. Ability of plasma GFAP to detect CSF amyloid pathology. ROC curves show the ability of plasma GFAP to detect CSF amyloid pathology. ROC curves have been built from logistic regression models taking CSF amyloid status as response and plasma GFAP values, age, sex, and ApoE ε4 status as predictor variables. X axis shows 1-specificity, and Y axis corresponds to sensitivity. Red curve corresponds to base model including age, sex, and ApoE ε4 status; the blue one corresponds to plasma GFAP along with age, sex, and ApoE ε4 status; the green one to plasma GFAP alone. Abbreviations: ROC, receiver operating characteristic. A, amyloid. AUC, area under the curve. GFAP, glial fibrillary acidic protein. CI, confidence interval

Article Snippet: Correlation plot of plasma GFAP levels measured with both Lumipulse and SIMOA techniques.

Techniques: Clinical Proteomics

Journal: Alzheimer's Research & Therapy

Article Title: Diagnostic performance of plasma GFAP in preclinical stages of Alzheimer’s disease using the Lumipulse platform

doi: 10.1186/s13195-026-02012-9

Figure Lengend Snippet: Agreement between Lumipulse and SIMOA assays. Figure 4 A . Correlation plot of plasma GFAP levels measured with both Lumipulse and SIMOA techniques. Blue dots indicate individual values; the red line represents the regression line, and the grey shaded area indicates the 95% confidence interval. Figure 4 B . Passing-Bablok regression plot. Green dots represent paired plasma GFAP measurements; the blue line is the Passing-Bablok regression line, and the red dashed line corresponds to the identity line (perfect agreement). Figure 4 C . Bland-Altman plot showing agreement between Lumipulse and SIMOA methods. The x-axis represents the mean of both measurements, and the y-axis shows their difference. The red dashed line indicates the mean bias, and the green dashed lines represent the limits of agreement (LoA) (bias ± 1.96 SD)

Article Snippet: Correlation plot of plasma GFAP levels measured with both Lumipulse and SIMOA techniques.

Techniques: Clinical Proteomics